Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API

MT Newswires Live

2024/09/12

Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.

Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.

The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.

Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2466214425"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466214425\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466214425?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-12 12:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466214425","market":"us","top_or_hot":-1,"title":"Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API","media":"MT Newswires Live","content":"<html><body><p>Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API</p><p> Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.</p><p>Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.</p><p>The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.</p><p>Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%</p></body></html>","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJinyao Pharmaceuticals Receives FDA Approval for Deflazacort API\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 12:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600488","symbol_name":"津药药业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466214425","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466214425","pubTimestamp":1726116519,"columns":[],"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API Jinyao Pharmaceutical (SHA:600488) ","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"600488":"津药药业","BK6100":"保健护理服务","BK0102":"重组","BK0012":"证金概念","BK0239":"医药制造","OTX.SI":"迈怡汇有限公司","BK6520":"工商业服务概念","BK0028":"国家队","DMF":"Dreyfus Municipal Income Inc"},"translate_title":"金耀药业Deflazacort原料药获FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600488":1,"DMF":1,"OTX.SI":1},"content_text":"Jinyao Pharmaceuticals Receives FDA Approval for Deflazacort API Jinyao Pharmaceutical (SHA:600488) has obtained a DMF or drug master files letter from the US Food and Drug Administration for its Deflazacort API, according to a Wednesday filing on the Shanghai Stock Exchange.Deflazacort is an active pharmaceutical ingredient widely used to treat Duchenne muscular dystrophy. The global market for Deflazacort preparations is estimated to have reached $106 million in 2023, Jinyao said.The FDA's approval of Jinyao Pharmaceuticals' DMF indicates that the company's Deflazacort API meets the quality standards required for use in the US.Price (RMB): Â¥3.78, Change: Â¥-0.020, Percent Change: -0.53%","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}